Bibliography
- LEE JC, KUMAR S, GRISWOLD DE et al.: Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology (2000) 47:185-201.
- HERLAAR E, BROWN Z: p38 MAPK signalling cascades in inflammatory disease. Mol. Med.Today. (1999) 5:439-448.
- BOEHM JC, ADAMS JL: New inhibitors of p38 kinase. Expert Opin. Ther. Patents (2000) 10:25-37.
- LEE MR, DOMINGUEZ C: MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38α protein. Curr. Med. Chem. (2005) 12(25):2979-2994.
- DOMINGUEZ C, POWERS DA, TAMAYO N: p38 MAP kinase inhibitors: many are made, but few are chosen. Curr. Opin. Drug Discov. Devel. (2005) 8(4):421-430.
- DOMINGUEZ C, TAMAYO N, ZHANG D: p38 Inhibitors: beyond pyridinylimidazoles. Expert Opin. Ther. Patents (2005) 15:801-816.
- SCHREIBER S, FEAGAN B, D'HAENS G et al.: Clin. Gastroenterol. Hepatol. (2006) 4(3):325-334.
- PARGELLIS C, TONG L, CHURCHILL L et al.: Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct. Biol. (2002) 9(4):268-272.
Patents
- ASTEX THERAPEUTICS LTD: WO03087087 (2003).
- JANSSEN PHARMACEUTICA NV: WO2004029040 (2004).
- ELI LILLY AND CO.: WO2006009741 (2006).
Websites
- www.locusdiscovery.com/ PDFs/P38_Drug_Discovery_4.05.05.pdf
- www.locusdiscovery.com/ PDFs/060314TechnologyValidation.pdf
- www.locusdiscovery.com/ PDFs/LocusCorporatePresentation.pdf